From €3486EUR$3,990USD£3,144GBP
- Drug Pipelines
- October 2020
- 105 Pages
From €2184EUR$2,500USD£1,970GBP
- Drug Pipelines
- October 2020
- 174 Pages
From €6072EUR$6,950USD£5,477GBP
- Report
- June 2020
- 222 Pages
From €2712EUR$3,104USD£2,446GBP
€3013EUR$3,449USD£2,718GBP
- Drug Pipelines
- May 2020
- 1460 Pages
From €2184EUR$2,500USD£1,970GBP
From €952EUR$1,090USD£859GBP
- Report
- March 2020
- 120 Pages
From €2184EUR$2,500USD£1,970GBP
- Drug Pipelines
- December 2019
- 1380 Pages
From €1747EUR$2,000USD£1,576GBP
- Report
- December 2019
- 200 Pages
From €3495EUR$4,000USD£3,152GBP
From €2805EUR$3,210USD£2,529GBP
- Report
- July 2020
- 86 Pages
From €746EUR$854USD£673GBP
€829EUR$949USD£748GBP
From €1546EUR$1,770USD£1,395GBP
- Report
- July 2020
- 102 Pages
From €1398EUR$1,600USD£1,261GBP
- Report
- May 2020
- 225 Pages
From €3495EUR$4,000USD£3,152GBP
- Report
- May 2020
- 89 Pages
From €1573EUR$1,800USD£1,418GBP
- Report
- May 2020
- 85 Pages
From €1573EUR$1,800USD£1,418GBP
From €3932EUR$4,500USD£3,546GBP
- Report
- December 2018
- 83 Pages
From €5198EUR$5,950USD£4,689GBP
- Drug Pipelines
- June 2017
- 77 Pages
From €4325EUR$4,950USD£3,901GBP
- Drug Pipelines
- June 2017
- 60 Pages
From €2141EUR$2,450USD£1,931GBP
Cervical cancer is the second most common and the fifth most deadly cancer in women. Approximately 80% of cervical cancers occur in developing countries which makes emerging economies such as China a major target market for pharmaceutical companies in the cervical cancer sector. The following expert reports enable buyers to examine the essential issues: supply and demand, forecasts, drug development and discovery, licensing, SWOT analyses, key industry players and more. This is the place for the inside track on market entry opportunities, growth strategies, buyer solutions and potential industry alliances in the area of cervical cancer drug development. Show Less Read more
